References

Safety & Effectiveness of COVID‐19 Vaccines: A Narrative Review

10.4103/ijmr.ijmr_474_21 · 2022 · External reference

Diabetes Mellitus Is Associated With Higher COVID‐19 Mortality Rates in Sub‐Saharan Africa: A Systematic Review and Meta‐Analysis

2022 · External reference

Risk of Mortality in HIV‐Infected COVID‐19 Patients: A Systematic Review and Meta‐Analysis

10.1016/j.jiph.2022.05.006 · 2022 · External reference

Effectiveness of COVID‐19 Vaccines in Adults With Diabetes Mellitus: A Systematic Review

10.3390/vaccines11010024 · 2022 · External reference

Could Widespread Use of Antiviral Treatment Curb the COVID‐19 Pandemic? A Modeling Study

10.1186/s12879-022-07639-1 · 2022 · External reference

Comparison of Effectiveness and Safety of Nirmatrelvir/Ritonavir Versus Sotrovimab for COVID‐19: A Systematic Review and Meta‐Analysis

10.1080/14787210.2024.2326561 · 2024 · External reference

Remdesivir in Solid Organ Transplant Recipients With COVID‐19: A Systematic Review and Meta‐Analysis

10.4285/ctr.24.0031 · 2024 · External reference

Effectiveness of Molnupiravir in the Treatment of Patients With COVID‐19: A Systematic Review and Meta‐Analysis

10.61186/umj.33.12.857 · 2023 · External reference

Effectiveness and Safety of Azvudine in COVID‐19: A Systematic Review and Meta‐Analysis

10.1371/journal.pone.0298772 · 2024 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Efficacy and Safety of Nirmatrelvir/Ritonavir (Paxlovid) for COVID‐19: A Rapid Review and Meta‐Analysis

10.1002/jmv.28441 · 2023 · External reference

Clinical Outcome and 7‐Day Virological Clearance in High‐Risk Patients With Mild–Moderate COVID‐19 Treated With Molnupiravir, Nirmatrelvir/Ritonavir, or Remdesivir

10.1007/s40121-024-00994-3 · 2024 · External reference

Nirmatrelvir/Ritonavir and Remdesivir Against Symptomatic Treatment in High‐Risk COVID‐19 Outpatients to Prevent Hospitalization or Death During the Omicron Era: A Propensity Score‐Matched Study

10.1177/20499361241236582 · 2024 · External reference

Effectiveness, Tolerability and Prescribing Choice of Antiviral Molecules Molnupiravir, Remdesivir and Nirmatrelvir/R: A Real‐World Comparison in the First Ten Months of Use

10.3390/v15041025 · 2023 · External reference

Effectiveness of Oral Nirmatrelvir/Ritonavir vs. Intravenous Three‐Day Remdesivir in Preventing Progression to Severe COVID‐19: A Single‐Center, Prospective, Comparative, Real‐Life Study

10.3390/v15071515 · 2023 · External reference

Early Administration of Nirmatrelvir/Ritonavir Leads to Faster Negative SARS‐CoV‐2 Nasal Swabs Than Monoclonal Antibodies in Covid 19 Patients at High‐Risk for Severe Disease

10.1186/s12985-024-02333-x · 2024 · External reference

Preferred Reporting Items for Systematic Reviews and Meta‐Analyses: The PRISMA Statement

10.1136/bmj.b2535 · 2009 · External reference

ROBINS‐I: A Tool for Assessing Risk of Bias in Non‐Randomised Studies of Interventions

10.1136/bmj.i4919 · 2016 · External reference

Outcomes of Targeted Treatment in Immunocompromised Patients With Asymptomatic or Mild COVID‐19: A Retrospective Study

10.1038/s41598-023-42727-5 · 2023 · External reference

Effectiveness of the Available Early Therapies in Reducing Severe COVID‐19 in Non‐Hospitalized Patients With Solid Tumors on Active Treatment

10.3389/fmed.2022.1036473 · 2022 · External reference

Safety and Efficacy of Outpatient Treatments for COVID‐19: Real‐Life Data From a Regionwide Cohort of High‐Risk Patients in Tuscany, Italy (The FEDERATE Cohort)

10.3390/v15020438 · 2023 · External reference

Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS‐CoV‐2 Infection in Hematological Patients and Cell Therapy Recipients

10.3390/v15102066 · 2023 · External reference

Mild SARS‐CoV‐2 Infection in Vulnerable Patients: Implementation of a Clinical Pathway for Early Treatment

10.1016/j.eimce.2023.03.003 · 2024 · External reference

Comparison Between Available Early Antiviral Treatments in Outpatients With SARS‐CoV‐2 Infection: A Real‐Life Study

10.1186/s12879-023-08538-9 · 2023 · External reference

Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real‐World Cohort of Outpatients With COVID‐19 at High Risk of Progression: The PISA Outpatient Clinic Experience

10.1007/s40121-022-00729-2 · 2023 · External reference

Monoclonal Antibody and Antiviral Therapy for Mild‐to‐Moderate COVID‐19 in Pediatric Patients

10.1097/inf.0000000000003740 · 2023 · External reference

Antiviral Use in Mild‐to‐Moderate SARS‐CoV‐2 Infections During the Omicron Wave in Geriatric Patients

10.3390/v16060864 · 2024 · External reference

Tixagevimab/Cilgavimab Prophylaxis Against COVID‐19 in Solid Organ Transplant Recipients: A Systematic Review and Meta‐Analysis

10.4285/ctr.24.0015 · 2024 · External reference

Comparative Efficacy and Safety of Nirmatrelvir/Ritonavir and Molnupiravir for COVID‐19: A Systematic Review and Meta‐Analysis

10.1002/jmv.28889 · 2023 · External reference

Efficacy and Safety of Regdanvimab in Patients With Mild to Moderate COVID‐19: A Rapid Review and Meta‐Analysis

10.1111/bcp.15676 · 2023 · External reference

10.7883/yoken.jjid.2024.372

10.7883/yoken.jjid.2024.372 · External reference

Mortality Benefit of Remdesivir in COVID‐19: A Systematic Review and Meta‐Analysis

10.3389/fmed.2020.606429 · 2021 · External reference

Clinical Efficacy and Safety of Remdesivir in Patients With COVID‐19: A Systematic Review and Network Meta‐Analysis of Randomized Controlled Trials

10.1093/jac/dkab093 · 2021 · External reference

Efficacy and Safety of Remdesivir in Hospitalized COVID‐19 Patients: Systematic Review and Meta‐Analysis Including Network Meta‐Analysis

10.1002/rmv.2187 · 2021 · External reference

Efficacy and Safety of Remdesivir in Hospitalised COVID‐19 Patients: A Systematic Review and Meta‐Analysis

10.1007/s15010-021-01671-0 · 2022 · External reference

Comparing the Effectiveness and Safety of Remdesivir and Molnupiravir in COVID‐19: A Systematic Review and Meta‐Analysis

10.1002/iid3.70289 · 2025 · External reference

Remdesivir Versus Sotrovimab in Coronavirus Disease 2019: A Systematic Review and Meta‐Analysis

10.1002/hsr2.71118 · 2025 · External reference

Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High‐Risk Patients

10.1093/cid/ciac443 · 2023 · External reference

A Retrospective Cohort Study of Paxlovid Efficacy Depending on Treatment Time in Hospitalized COVID‐19 Patients

10.7554/elife.89801 · 2024 · External reference

Paxlovid Associated With Decreased Hospitalization Rate Among Adults With COVID‐19—United States, April–September 2022

10.15585/mmwr.mm7148e2 · 2022 · External reference

Hospitalization and Emergency Department Encounters for COVID‐19 After Paxlovid Treatment—California, December 2021–May 2022

10.15585/mmwr.mm7125e2 · 2022 · External reference

Safety and Efficacy of Paxlovid Against Omicron Variants of Coronavirus Disease 2019 in Elderly Patients

10.1007/s40121-023-00760-x · 2023 · External reference

The Efficacy of Paxlovid in Elderly Patients Infected With SARS‐CoV‐2 Omicron Variants: Results of a Non‐Randomized Clinical Trial

10.3389/fmed.2022.980002 · 2022 · External reference

Risk of Hospitalization and Sequelae in Patients With COVID‐19 Treated With 3‐Day Early Remdesivir vs. Controls in the Vaccine and Omicron Era: A Real‐Life Cohort Study

10.1002/jmv.28660 · 2023 · External reference

Remdesivir Significantly Reduces SARS‐CoV‐2 Viral Load on Nasopharyngeal Swabs in Hospitalized Patients With COVID‐19: A Retrospective Case‐Control Study

10.1002/jmv.27598 · 2022 · External reference

Efficacy and Safety of Paxlovid (Nirmatrelvir/Ritonavir) in the Treatment of COVID‐19: An Updated Meta‐Analysis and Trial Sequential Analysis

10.1002/rmv.2473 · 2023 · External reference

Remdesivir Treatment in Hospitalized Patients Affected by COVID‐19 Pneumonia: A Case‐Control Study

10.1002/jmv.27768 · 2022 · External reference

Remdesivir for the Treatment of COVID‐19: A Narrative Review

10.1007/s40121-023-00900-3 · 2024 · External reference

Early Administration of Remdesivir to COVID‐19 Patients Associates With Higher Recovery Rate and Lower Need for Icu Admission: A Retrospective Cohort Study

10.1371/journal.pone.0258643 · 2021 · External reference

Azvudine Versus Paxlovid in COVID‐19: A Systematic Review and Meta‐Analysis

10.1002/rmv.2551 · 2024 · External reference

Cardiac Adverse Events Associated With Remdesivir in COVID‐19 Patients: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials

10.1136/bmjopen-2024-089977 · 2025 · External reference

Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications

10.1002/cpt.2646 · 2022 · External reference

Adverse Events Following Remdesivir Administration in Moderately Ill COVID‐19 Patients‐A Retrospective Analysis

10.4103/jfmpc.jfmpc_2468_21 · 2022 · External reference